Revision as of 13:14, 3 October 2022 by Blsimpso (talk | contribs) (→‎Pharmacology)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)


  • Type: Corticosteroid
  • Dosage Forms: IM; IV
  • Common Trade Names: Medrol, Solu-Medrol

Adult Dosing


  • 125mg IV

Pediatric Dosing


  • 2mg/kg

Special Populations

  • Pregnancy Rating: C(US)
  • Lactation: Oral maternal doses to 8mg daily is safe. Recommend waiting 2-8 hours after infusion of 1 gm. [1]
  • Renal Dosing
    • Adult: not available
    • Pediatric: not available
  • Hepatic Dosing
    • Adult: not available
    • Pediatric: not available

Controversial Use in Spinal Cord Injury

  • Steroid use for spinal cord injury was a controversial treatment during the 1990s and 2000s, with the NASCIS II and III studies reporting positive outcomes in a subgroup analysis of patients who received methylpredisolone within 8 hours of injury. Multiple cochrane reviews performed by the author of the NASCIS trials concluded neurological improvement after injury, but a review of all individual studies demonstrate negative outcomes for both the retrospective and the prospective trials[2]. Most recent guidelines from the Congress of Neurological Surgeons and American Association of Neurological Surgeons discourage against the use of steroids in spinal cord injury, citing harmful side effects including death.[3]


  • Allergy to class/drug

Adverse Reactions




  • Half-life: 0.25 hours (IV)[4]
  • Metabolism: Hepatic
  • Excretion: Urine excretion
  • Mechanism of Action: Potent anti-inflammatory properties with minimal mineralocorticoid activity

See Also


  1. Lactmed: Methylprednisolone
  2. Steroids for Spinal Cord Injury
  3. Anderson P. New CNS/AANS Guidelines Discourage Steroids in Spinal Injury. Medscape Medical News. Mar 28 2013
  4. Ocejo A, Correa R. Methylprednisolone. [Updated 2022 May 22]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: